Polyphor AG / Key word(s): Study results
07-Jun-2019 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Allschwil, Switzerland, June 7, 2019
Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Polyphor AG (SIX: POLN) presented yesterday new data from pulmonary delivery of its lead antibacterial candidate of the novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class, murepavadin, at the 42nd European Cystic Fibrosis Conference in Liverpool, United Kingdom.
The results from an in vivo study, which investigated the pharmacokinetics, tolerability and efficacy of murepavadin in neutropenic mouse lung infection models against Pseudomonas aeruginosa (PA), demonstrated linear, dose proportional, pharmacokinetics when administered by intratracheal application. Exposure of the epithelial lining fluid to murepavadin was favorable compared to that in plasma. Murepavadin displayed potent activity toward PA infections when delivered intratracheally. Initial experiments further suggest that murepavadin was well tolerated when administered by inhalation route.
In order to support and accelerate the development of a novel inhaled formulation of murepavadin, Polyphor is leveraging a European program dedicated to the development of inhaled antibiotics, iABC (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis). The iABC project is a Europe-wide program run by a consortium of leading lung specialists in 18 hospitals and research institutions in eight European countries. These institutions will receive up to EUR 5 million funding for this project, under grant agreement 115721 from the Innovative Medicines Initiative (IMI), a public-private partnership of EFPIA (European Federation of Pharmaceutical Industries and Associations) and the EU, while Polyphor will invest up to EUR 5 million.
“Respiratory infections, especially those caused by drug-resistant bacteria, are the main cause of disease and death in people with cystic fibrosis and bronchiectasis. New treatment options are urgently needed to fight resistant pathogens, especially resistant Pseudomonas strains,” commented Daniel Obrecht, Chief Scientific Officer of Polyphor. “Murepavadin is a precision antibiotic specifically targeting Pseudomonas aeruginosa, the main cause of chronic lung infection in cystic fibrosis. The in vivo data presented are encouraging and we are looking forward to further developing the inhaled formulation of murepavadin within the iABC project, which will be an important step to find a new treatment option to improve the quality of life and increase life expectancy of these patients.”
For further information please contact:
End of ad hoc announcement
|Phone:||+41 61 567 1600|
|Fax:||+41 61 567 1601|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||820997|
|End of Announcement||EQS Group News Service|